Jupiter Neurosciences (JUNS) Change in Accured Expenses (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Change in Accured Expenses of -$21022.0 for Q4 2025, up 70.47% year-over-year from -$12331.8 in Q4 2024, and up 87.93% quarter-over-quarter from -$174195.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Change in Accured Expenses (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Change in Accured Expenses for 3 consecutive years, with -$21022.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 70.47% year-over-year to -$21022.0; the TTM figure through Dec 2025 stood at -$17736.0 (down 138.25% YoY), while the FY2025 annual figure was -$17736.0, down 138.25% from the prior year.
- Change in Accured Expenses grew to -$21022.0 in Q4 2025 per JUNS's latest filing, from -$174195.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $184916.0 in Q2 2025 and bottomed at -$174195.0 in Q3 2025.
- Historically, Change in Accured Expenses has averaged -$1158.4 across 3 years, with a median of -$7435.0 in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 809.71% in 2025 and fell as far as 322.91% in 2025.
- Jupiter Neurosciences' Change in Accured Expenses stood at -$39058.0 in 2023, then tumbled by 82.26% to -$71187.0 in 2024, then surged by 70.47% to -$21022.0 in 2025.
- Business Quant data shows JUNS's Change in Accured Expenses at -$21022.0 in Q4 2025, -$174195.0 in Q3 2025, and $184916.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21,022.00 |
| Dec 31, 2025 | -21,022.00 |
| Sep 30, 2025 | -174,195.00 |
| Sep 30, 2025 | -174,195.00 |
| Jun 30, 2025 | 184,916.00 |
| Jun 30, 2025 | 184,916.00 |
| Mar 31, 2025 | -7,435.00 |
| Mar 31, 2025 | -7,435.00 |
| Dec 31, 2024 | -71,187.00 |
| Dec 31, 2024 | -71,187.00 |
| Sep 30, 2024 | 78,145.00 |
| Sep 30, 2024 | 78,145.00 |
| Jun 30, 2024 | 20,327.00 |
| Jun 30, 2024 | 20,327.00 |
| Mar 31, 2024 | 19,083.00 |
| Mar 31, 2024 | 19,083.00 |
| Dec 31, 2023 | -39,058.00 |
| Dec 31, 2023 | -39,058.00 |